BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 17493703)

  • 1. Administration of miglitol until 30 min after the start of a meal is effective in type 2 diabetic patients.
    Aoki K; Nakamura A; Ito S; Nezu U; Iwasaki T; Takahashi M; Kimura M; Terauchi Y
    Diabetes Res Clin Pract; 2007 Oct; 78(1):30-3. PubMed ID: 17493703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Divided-dose administration of miglitol just before and 15 minutes after the start of a meal smoothes postprandial plasma glucose excursions and serum insulin responses in healthy men.
    Aoki K; Kato H; Terauchi Y
    Endocr J; 2007 Dec; 54(6):1009-14. PubMed ID: 18048991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of efficacy and safety of taking miglitol dissolved in water during a meal and taking a miglitol tablet just before a meal in patients with type 2 diabetes.
    Shibata E; Aoki K; Tajima K; Taguri M; Terauchi Y
    Expert Opin Pharmacother; 2016; 17(7):889-94. PubMed ID: 26918556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of pre- vs. postmeal administration of miglitol for 3 months in type 2 diabetic patients.
    Aoki K; Nakajima S; Nezu U; Shinoda K; Terauchi Y
    Diabetes Obes Metab; 2008 Sep; 10(10):970-2. PubMed ID: 18721256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition.
    Johnston PS; Feig PU; Coniff RF; Krol A; Kelley DE; Mooradian AD
    Diabetes Care; 1998 Mar; 21(3):416-22. PubMed ID: 9540025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-dependent efficacy of miglitol, an alpha-glucosidase inhibitor, in type 2 diabetic patients on diet alone: results of a 24-week double-blind placebo-controlled study.
    Drent ML; Tollefsen AT; van Heusden FH; Hoenderdos EB; Jonker JJ; van der Veen EA
    Diabetes Nutr Metab; 2002 Jun; 15(3):152-9. PubMed ID: 12173729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.
    Lee A; Patrick P; Wishart J; Horowitz M; Morley JE
    Diabetes Obes Metab; 2002 Sep; 4(5):329-35. PubMed ID: 12190996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients.
    Johnston PS; Feig PU; Coniff RF; Krol A; Davidson JA; Haffner SM
    Diabetes Care; 1998 Mar; 21(3):409-15. PubMed ID: 9540024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients.
    Johnston PS; Lebovitz HE; Coniff RF; Simonson DC; Raskin P; Munera CL
    J Clin Endocrinol Metab; 1998 May; 83(5):1515-22. PubMed ID: 9589648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of miglitol and glibenclamide in diet-treated type 2 diabetic patients.
    Pagano G; Marena S; Corgiat-Mansin L; Cravero F; Giorda C; Bozza M; Rossi CM
    Diabete Metab; 1995 Jun; 21(3):162-7. PubMed ID: 7556806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of pre-meal versus post-meal administration of miglitol on plasma glucagon-like peptide-1 and glucosedependent insulinotropic polypeptide levels in healthy men.
    Aoki K; Miyazaki T; Nagakura J; Orime K; Togashi Y; Terauchi Y
    Endocr J; 2010; 57(8):673-7. PubMed ID: 20519807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the α-glucosidase inhibitor miglitol on the glucose profile in Japanese type 2 diabetic patients receiving multiple daily insulin injections.
    Kato H; Ohta A; Kobayashi S; Ishii S; Sada Y; Kobayashi H; Ohmori S; Kondo A; Katabami T; Fuse J; Fukuda H; Nagai Y; Tanaka Y
    Endocr J; 2012; 59(4):345-52. PubMed ID: 22301938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.
    Aoki K; Kamiyama H; Yoshimura K; Shibuya M; Masuda K; Terauchi Y
    Acta Diabetol; 2012 Jun; 49(3):225-30. PubMed ID: 21898126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.
    Kishimoto M; Noda M
    Cardiovasc Diabetol; 2011 Dec; 10():115. PubMed ID: 22189184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does suppression of postprandial blood glucose excursions by the alpha-glucosidase inhibitor miglitol improve insulin sensitivity in diet-treated type II diabetic patients?
    Johnson AB; Taylor R
    Diabetes Care; 1996 Jun; 19(6):559-63. PubMed ID: 8725851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus.
    Mitrakou A; Tountas N; Raptis AE; Bauer RJ; Schulz H; Raptis SA
    Diabet Med; 1998 Aug; 15(8):657-60. PubMed ID: 9702468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of 3-month repeated administration of miglitol on vascular endothelial function in patients with diabetes mellitus and coronary artery disease.
    Emoto T; Sawada T; Hashimoto M; Kageyama H; Terashita D; Mizoguchi T; Mizuguchi T; Motodi Y; Iwasaki M; Taira K; Okamoto H; Matsuo Y; Kim SK; Takarada A; Yokoyama M
    Am J Cardiol; 2012 Jan; 109(1):42-6. PubMed ID: 21944671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease - Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diabetic patients with coronary heart disease (J-MACH) -.
    Hiki M; Shimada K; Kiyanagi T; Fukao K; Hirose K; Ohsaka H; Fukushima Y; Kume A; Matsumori R; Sumiyoshi K; Miyazaki T; Ohmura H; Kurata T; Miida T; Daida H
    Circ J; 2010 Jul; 74(7):1471-8. PubMed ID: 20519875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of miglitol as an add-on to bolus insulin on postprandial glycemic excursions in type 2 diabetes patients assessed by continuous glucose monitoring.
    Matsuura K; Mori Y; Nakamura A; Yokoyama J; Utsunomiya K
    Diabetes Technol Ther; 2012 May; 14(5):423-9. PubMed ID: 22316114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. alpha-Glucosidase inhibition by miglitol in NIDDM patients.
    Kingma PJ; Menheere PP; Sels JP; Nieuwenhuijzen Kruseman AC
    Diabetes Care; 1992 Apr; 15(4):478-83. PubMed ID: 1499461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.